Shots:
- Samsung Biologics has launched an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide, expanding its capabilities beyond antibodies & ADCs to include peptide therapeutics
- As per the deal, PolyPeptide will receive CHF 44.31 (~$54.8) in cash per share, representing an implied equity value of ~CHF 1.46B (~$1.8B); closing is expected towards the end of 2026, subject to customary offer conditions
- Following the transaction, Samsung Biologics will integrate PolyPeptide’s experienced team & peptide expertise, combining scientific capabilities, manufacturing strengths, & global operations
Ref: PRnewswire | Image: PolyPeptide | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
